JP2021522180A5 - - Google Patents
Info
- Publication number
- JP2021522180A5 JP2021522180A5 JP2020557256A JP2020557256A JP2021522180A5 JP 2021522180 A5 JP2021522180 A5 JP 2021522180A5 JP 2020557256 A JP2020557256 A JP 2020557256A JP 2020557256 A JP2020557256 A JP 2020557256A JP 2021522180 A5 JP2021522180 A5 JP 2021522180A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- antibody preparation
- sodium phosphate
- buffered
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658772P | 2018-04-17 | 2018-04-17 | |
| US62/658,772 | 2018-04-17 | ||
| US201862776686P | 2018-12-07 | 2018-12-07 | |
| US62/776,686 | 2018-12-07 | ||
| PCT/US2019/027790 WO2019204380A1 (en) | 2018-04-17 | 2019-04-17 | Buffered formulations of bevacizumab for use of treating diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522180A JP2021522180A (ja) | 2021-08-30 |
| JP2021522180A5 true JP2021522180A5 (enExample) | 2022-04-22 |
Family
ID=66429576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557256A Pending JP2021522180A (ja) | 2018-04-17 | 2019-04-17 | ベバシズマブの緩衝製剤を用いる疾患の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210230261A1 (enExample) |
| EP (1) | EP3781199A1 (enExample) |
| JP (1) | JP2021522180A (enExample) |
| KR (1) | KR20210011923A (enExample) |
| CN (1) | CN112543645A (enExample) |
| AU (1) | AU2019256289A1 (enExample) |
| BR (1) | BR112020021255A2 (enExample) |
| CA (1) | CA3097123A1 (enExample) |
| IL (1) | IL278041A (enExample) |
| MX (1) | MX2020010968A (enExample) |
| SG (1) | SG11202010178XA (enExample) |
| WO (1) | WO2019204380A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP7713950B2 (ja) * | 2020-03-04 | 2025-07-28 | 上海復宏漢霖生物技術股▲フン▼有限公司 | ベバシズマブを含む薬物製剤 |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| WO2012019136A2 (en) * | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| CA3010329A1 (en) * | 2015-12-29 | 2017-07-06 | Oncobiologics, Inc. | Buffered formulations of bevacizumab |
| CN106924184B (zh) * | 2017-03-29 | 2020-07-17 | 烟台大学 | 一种眼部玻璃体注射用多囊脂质体及其制备方法 |
-
2019
- 2019-04-17 AU AU2019256289A patent/AU2019256289A1/en not_active Abandoned
- 2019-04-17 CN CN201980040536.7A patent/CN112543645A/zh active Pending
- 2019-04-17 WO PCT/US2019/027790 patent/WO2019204380A1/en not_active Ceased
- 2019-04-17 BR BR112020021255-5A patent/BR112020021255A2/pt not_active IP Right Cessation
- 2019-04-17 US US17/048,107 patent/US20210230261A1/en not_active Abandoned
- 2019-04-17 JP JP2020557256A patent/JP2021522180A/ja active Pending
- 2019-04-17 MX MX2020010968A patent/MX2020010968A/es unknown
- 2019-04-17 SG SG11202010178XA patent/SG11202010178XA/en unknown
- 2019-04-17 KR KR1020207033144A patent/KR20210011923A/ko not_active Abandoned
- 2019-04-17 EP EP19722351.4A patent/EP3781199A1/en not_active Withdrawn
- 2019-04-17 CA CA3097123A patent/CA3097123A1/en active Pending
-
2020
- 2020-10-14 IL IL278041A patent/IL278041A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| Wong et al. | Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| JP2019521156A5 (enExample) | ||
| CN117159463A (zh) | 治疗青光眼的Wnt5a的调节 | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| JP2022527276A (ja) | 眼疾患を治療するための組成物及び方法 | |
| JPH078805B2 (ja) | 眼の発育の神経ペプチド制御 | |
| Moon et al. | Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis | |
| CN114929245A (zh) | 用于治疗干性年龄相关性黄斑变性(amd)或继发于干性amd的地图样萎缩的抗c5剂 | |
| Sidorova et al. | The study of the efficiency of micropulse transscleral cyclophotocoagulation in the combined treatment of patients with secondary neovascular glaucoma | |
| Lam et al. | Iris crystals in chronic iridocyclitis | |
| RU2020137402A (ru) | Способы лечения заболевания с использованием забуференных составов бевацизумаба | |
| WO1998001137A1 (en) | The ocular hypotensive active compositions | |
| RU2395318C1 (ru) | Способ лечения скрытых субретинальных неоваскулярных мембран | |
| JP2024531861A (ja) | Ｓｇｌｔ－２阻害剤を含む糖尿病性眼疾患の予防または治療用薬学的組成物 | |
| RU2481112C1 (ru) | Способ лечения заболеваний роговицы, сетчатки и зрительного нерва у собак | |
| RU2484795C2 (ru) | Способ индукции задней отслойки стекловидного тела с помощью миниплазмина | |
| US20040259844A1 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| EP4719387A2 (en) | Complement antibody-drug conjugates | |
| JP2025517038A (ja) | 黄斑浮腫又は網膜静脈閉塞の治療における使用のための単量体アネキシンａ５ | |
| CN121015648A (zh) | 异丙托溴铵在预防改善近视方面的应用及一种含异丙托溴铵的滴眼液 | |
| RU2488891C1 (ru) | Способ моделирования неоваскуляризации переднего отрезка глаза у крыс | |
| CN116515827A (zh) | 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用 |